# CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS

Study · id `cardio:ct-nct07612774` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07612774](<https://clinicaltrials.gov/study/NCT07612774>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07612774

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 232 participants.

## Technical summary

Registry record NCT07612774. Randomized; triple masking; primary purpose treatment. Start 2025-11-19 (actual); primary completion 2028-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 232 participants (planned count; ClinicalTrials.gov record NCT07612774, source copy `cardio:ctgov-nct07612774-2026-10-07`, retrieved 2026-10-26)
- Started: 2025-11-19 (actual) (ClinicalTrials.gov record NCT07612774, source copy `cardio:ctgov-nct07612774-2026-10-07`, retrieved 2026-10-26)
- Primary completion: 2028-10-31 (anticipated) (ClinicalTrials.gov record NCT07612774, source copy `cardio:ctgov-nct07612774-2026-10-07`, retrieved 2026-10-26)
- Completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT07612774, source copy `cardio:ctgov-nct07612774-2026-10-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07612774, source copy `cardio:ctgov-nct07612774-2026-10-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07612774-2026-10-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS
- Acronym: CAPRA-EVO
- Condition: Coronary
- Condition: Coronary Artery Disease
- Intervention (Drug): Evolocumab
- Intervention (Diagnostic test): Serial photon-counting coronary computed tomography angiography
- Intervention (Drug): Standard Lipid-Lowering Therapy
- Lead sponsor: West China Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: West China Hospital (`cardio:org-west-china-hospital`)

## Provenance

Content hash: 9512b49e3d248c2b1b9f45c74892ca957ac2b0d1e2d2371d03cc39c5b0c714ea
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
